Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
angiotensin-converting enzyme inhibitor + non-dihydropyridine calcium channel blocker
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Angiotensin-converting enzyme inhibitor + non-dihydropyridine calcium channel blocker** refers to a specific drug combination used for the treatment of hypertension and cardiovascular diseases. It consists of an ACE inhibitor (which blocks the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced blood pressure) and a non-dihydropyridine calcium channel blocker (which blocks calcium influx in cardiac and vascular smooth muscle, leading to vasodilation, reduction of heart rate, and decreased force of contraction)[4][5][2]. This combination targets multiple pathways in blood pressure regulation, leading to greater efficacy for hypertension, improved tolerability, and additional organ protection (particularly in the heart and kidneys)[3][1][6]. The combination has been shown to reduce side effects commonly associated with each class when used alone, such as peripheral edema (associated with dihydropyridine CCBs) and cough (with ACE inhibitors), and is used in fixed-dose or separate-agent regimens. Trandolapril + verapamil is an example of a fixed-dose combination in this class[1][2].
- Other names
- ace inhibitor + non-dihydropyridine calcium channel blocker
02
Targets
ACE (Angiotensin Converting Enzyme)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on angiotensin-converting enzyme inhibitor + non-dihydropyridine calcium channel blocker.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on angiotensin-converting enzyme inhibitor + non-dihydropyridine calcium channel blocker.